Clinical Trial Update: QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial update shows recruitment is ongoing for QL1706 plus chidamide as first-line therapy for metastatic pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Chidamide (chidamide)
• QL1706

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: RECRUITING